A comprehensive analysis published in JAMA sheds light on the pervasive financial relationships between physicians and the pharmaceutical and medical device industries. Led by a team from Penn State College of Medicine, the study examined data from the Open Payments platform, revealing that doctors received approximately $12.1 billion from drug and device makers between 2013 and 2022.
The analysis, one of the first longitudinal studies of its kind, underscores the enduring prevalence of financial conflicts of interest in medical practice and research. Despite efforts to enhance transparency through initiatives like the Physician Payments Sunshine Act, which led to the establishment of the Open Payments database, financial relationships between physicians and industry remain widespread.
Lead author Andrew Foy emphasizes the need for broader public discourse on the implications of these findings. While Open Payments provides valuable insights into physician-industry transactions, questions linger about the necessity for deterrence or behavioral change.
The study encompassed payments across 39 specialties, revealing within-specialty variations in payment amounts. Orthopedic surgeons emerged as top recipients, while pediatric surgeons received the least. Additionally, the analysis identified the 25 drugs and medical devices associated with the largest total payments, highlighting the substantial financial ties between physicians and specific products.
With over half of physicians receiving at least one payment and the majority of payments linked to marketed medical products, the study underscores the importance of ongoing scrutiny and accountability measures to safeguard patient trust and uphold ethical standards in medical practice.
More: https://medicalxpress.com/news/2024-03-doctors-approximately-billion-drug-device.html
